So I guess the question with CEPT inhibitors almost in the grave, given that it was the big companies that put their money into developing and testing this theory and having it fail what might this imply about a "tiny little Calgary based biotech with what is seemingly little credibility".
- Will it begin to focus eyes on Resverlogix as a serious contender?
- Or will it create a very skeptical BP and investor market to become very cautious?
I'd be amazed if this does not focus serious attention on RVX and yet the CEPT failures are not new.
IMO
Toinv
